Emerphed is a drug owned by Nexus Pharmaceuticals Llc. It is protected by 5 US drug patents filed from 2021 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2040. Details of Emerphed's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | Active |
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Emerphed's patents.
Latest Legal Activities on Emerphed's Patents
Given below is the list of recent legal activities going on the following patents of Emerphed.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 14 Jun, 2023 | US11464752 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Jun, 2023 | US11241400 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Jun, 2023 | US11464752 |
| Electronic Review Critical | 14 Jun, 2023 | US11464752 |
| Electronic Review Critical | 14 Jun, 2023 | US11090278 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Jun, 2023 | US11090278 (Litigated) |
| Email Notification Critical | 14 Jun, 2023 | US11090278 (Litigated) |
| Electronic Review Critical | 14 Jun, 2023 | US11241400 |
| Email Notification Critical | 14 Jun, 2023 | US11241400 |
| Change in Power of Attorney (May Include Associate POA) Critical | 14 Jun, 2023 | US11478436 |
US patents provide insights into the exclusivity only within the United States, but Emerphed is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Emerphed's family patents as well as insights into ongoing legal events on those patents.
Emerphed's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Emerphed's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Emerphed Generic API suppliers:
Ephedrine Sulfate is the generic name for the brand Emerphed. 12 different companies have already filed for the generic of Emerphed, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Emerphed's generic
How can I launch a generic of Emerphed before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Emerphed's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Emerphed's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Emerphed -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 50 mg/10 mL | 14 Oct, 2021 | 1 | 16 May, 2040 |
Alternative Brands for Emerphed
Emerphed which is used for increasing blood pressure in cases of hypotension., has several other brand drugs using the same active ingredient (Ephedrine Sulfate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bayer Healthcare Llc |
| |
| Endo Operations |
| |
| Organon |
| |
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ephedrine Sulfate, Emerphed's active ingredient. Check the complete list of approved generic manufacturers for Emerphed
About Emerphed
Emerphed is a drug owned by Nexus Pharmaceuticals Llc. It is used for increasing blood pressure in cases of hypotension. Emerphed uses Ephedrine Sulfate as an active ingredient. Emerphed was launched by Nexus in 2023.
Approval Date:
Emerphed was approved by FDA for market use on 28 February, 2023.
Active Ingredient:
Emerphed uses Ephedrine Sulfate as the active ingredient. Check out other Drugs and Companies using Ephedrine Sulfate ingredient
Treatment:
Emerphed is used for increasing blood pressure in cases of hypotension.
Dosage:
Emerphed is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/10ML (5MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 25MG/5ML (5MG/ML) | SOLUTION | Prescription | INTRAVENOUS |